Reason for request

Re-assessment of the Actual Benefit of all medicines indicated for menopausal hormone replacement therapy at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code and OROMONE 1 mg and 2 mg: renewal of inclusion

-


Clinical Benefit

Substantial

The actual benefit of the proprietary medicinal products OESCLIM 25 μg/24 hours /24h, 37.5 μg/24 hours, 50 μg/24 hours and OROMONE 1 mg, 2 mg in hormone replacement therapy (HRT) for symptoms of oestrogen deficiency in menopausal women remains substantial in patients for whom climacteric disorders are described as troublesome enough to impair their quality of life when these proprietary medicinal products are used as per the Committee's recommendations.


Therapeutic use

-